A research peptide project can reach an attractive packaging design while still lacking an agreed record of who approves the material identity, reviews a revised COA or accepts a change in presentation. A quality agreement makes those responsibilities explicit before the parties rely on them.
For OEM, ODM, CRO and CDMO discussions, begin with the intended research context and the proposed deliverables. Service names describe possible relationships. The project brief and accepted agreement determine what each organization will actually provide. A research-only label does not replace those decisions or establish eligibility for another intended use.
Define the agreement’s purpose and limits
FDA’s November 2016 guidance on quality agreements for contract drug activities discusses documenting the parties’ responsibilities in a CGMP context. That scope should remain clear. It is not a blanket regulatory obligation for every research-use-only catalog transaction.
The responsibility questions below are our commercial and quality-documentation recommendations for eligible institutional research projects. They do not establish drug approval, GMP status or a promise that a proposed project can proceed. Applicable legal obligations and contract terms require their own review for the actual parties, material and destination.
A quotation answers questions about the offered material, commercial conditions and included deliverables. A quality agreement can explain who controls the associated specifications and records over time. Keep the documents consistent and identify which versions form the accepted project package.
Turn a service label into defined deliverables
| Discussion | Responsibility to define | Record to agree |
|---|---|---|
| OEM or private-label presentation | Who approves product wording, variable label fields and artwork | Approved specification and artwork revision |
| ODM project concept | Who defines the brief and accepts the proposed presentation | Feasibility scope, decision record and agreed deliverables |
| CRO engagement | Who owns the research question, reporting scope and record-access decision | Statement of work, confidentiality terms and reporting responsibilities |
| CDMO engagement | Who coordinates the eligible development and supply responsibilities | Project scope, milestones and quality-documentation responsibilities |
These descriptions are prompts for a project discussion, not a universal definition of every supplier’s service. A company may use the same abbreviation for a different scope. Ask for the actual deliverables and exclusions, including any work that requires separate qualification.
Keep identity and specification in a controlled annex
Attach or reference the accepted material designation, nominal presentation, document requirements and intended-use wording. Each item should have an identifiable revision or acceptance record. The label, quotation and batch-document request should use compatible designations.
Variable fields need their own approval route
A brand design can remain stable while the material name, batch reference or nominal quantity changes between presentations. Name the person or organization responsible for approving each variable field. Approving a general visual design should not be treated as approval of later product-specific statements.
Analytical claims need an identified source
List the evidence expected for the proposed material and who will provide it. If laboratory accreditation matters to the buyer, specify the required scope and verification route. If a record is unavailable, resolve that gap before describing it as an included deliverable. Our testing-scope guide covers this review.
Agree which changes require review
A useful agreement distinguishes a notification from a request for approval. The parties should decide which changes affect an accepted specification and which can be recorded as administrative updates. Avoid allowing a catalog edit to redefine a project requirement without a documented decision.
| Proposed change | Review question | Record to retain |
|---|---|---|
| Material designation or presentation | Does the institution need to accept a revised specification? | Change request and the accepted version |
| Analytical reporting scope or issuer | Does the evidence still meet the agreed requirement? | Issuer clarification and review outcome |
| Label or carton artwork | Are identity and intended-use fields accurate for this presentation? | Approved artwork proof |
| Transport proposal | Is the revised proposal compatible with documented requirements? | Agreed shipping and documentation terms |
| COA correction | Which decisions relied on the superseded version? | Revision history and recipient notification |
The agreement can identify a contact route and an agreed response process without inventing a universal deadline. Timing, escalation and acceptance responsibilities should reflect the project. The COA revision guide explains the records a correction may need.
Define record access, ownership and retention
State who can request a record, what can be disclosed and how confidential information will be handled. Keep the recipient’s ability to retrieve accepted documents separate from a general promise of “full traceability”. A buyer needs to know which records the supplier will actually make available.
OECD’s GLP Data Integrity guidance treats data as having a lifecycle within its stated GLP scope. In a research supply agreement, a useful question is who will preserve and retrieve the agreed project records after a contact changes or an engagement ends. Set retention and access terms for the specific project rather than borrowing an unsupported duration from another industry.
Ownership of artwork, supplied documents and commissioned work may differ. The parties should identify those rights expressly with appropriate contract review. The initial inquiry should describe the business requirement without disclosing confidential formulas, unpublished study detail or personal health information.
Close the project with an acceptance package
Before accepting an offer, reconcile the project scope, specification revision, document list, artwork status and unresolved questions. Record who accepts each part. A later shipment should be assessed against that accepted package and its documented changes.
Hytanbio-Tech can discuss eligible peptide projects through the OEM, ODM, CRO and CDMO inquiry route. Send the material identity, intended institutional market, presentation, documentation needs and destination through the project form. Feasibility, availability, commercial terms and responsibilities are confirmed individually.
Frequently asked questions
What should a research peptide quality agreement define?
It should identify the accepted project scope, responsibility for specifications and artwork, expected records, access arrangements, change review and acceptance decisions. The parties agree the details for the actual project.
Is FDA's drug quality-agreement guidance a blanket rule for RUO transactions?
No. The cited guidance addresses contract drug activities in a CGMP context. Its scope must remain distinct from a research-use-only supply discussion and the applicable obligations of the actual project.
Does approving a label design approve every future batch field?
No. Product designation, batch reference and nominal quantity need an agreed approval route for the actual presentation. A stable brand design does not settle later variable fields.
Can an OEM or CDMO label replace a written project brief?
No. Ask for the actual deliverables, exclusions, document responsibilities and acceptance records. Service abbreviations alone do not establish the work included or the project's regulatory status.
Sources and scope
- U.S. Food and Drug Administration: Contract Manufacturing Arrangements for Drugs: Quality Agreements.
- Organisation for Economic Co-operation and Development: GLP Data Integrity, Series No. 22.
Sources checked 31 October 2026. The procurement recommendations are Hytanbio-Tech editorial guidance. References define their own technical or regulatory scope and do not certify an offered material or this website.
For research use only. Not for human, veterinary or diagnostic use. This resource provides no experimental or administration instructions.